ArticleJournal of clinical practice and research2024
Ocular Tuberculosis, Anti-Tuberculosis Prophylaxis, and Diseases Confused with Ocular Tuberculosis: Brief Report.
Article in Journal of clinical practice and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case series of eight patients with ocular tuberculosis (OTB), latent tuberculosis (TB) or sarcoidosis, some of whom were receiving anti-tumor necrosis factor alpha (anti-TNF-α) therapy for various systemic diseases. Only one patient had a positive QuantiFERON®-TB test (QFT), and only one case showed a positive acid-resistant bacilli (ARB) test result. In a third case, brain imaging provided valuable assistance. Ocular tuberculosis should not be overlooked during clinical examination, as it remains a relevant diagnosis even in non-endemic regions. Over the last decade, the use of anti-TNF-α inhibitors for treating resistant uveitis has increased significantly. Consequently, it is essential to closely monitor patients for immunosuppression and remain vigilant about the risk of TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.